<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253266</url>
  </required_header>
  <id_info>
    <org_study_id>01/2005</org_study_id>
    <secondary_id>2005-001217-17</secondary_id>
    <nct_id>NCT00253266</nct_id>
  </id_info>
  <brief_title>Venlafaxine Augmentation in Treatment Resistant Depression</brief_title>
  <official_title>Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max-Planck-Institute of Psychiatry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max-Planck-Institute of Psychiatry</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic
      quetiapine in treatment resistant depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We examine the efficacy of Venlafaxine-HCL augmentation with the neuroleptic Quetiapine in
      treatment resistant depression in a double-blind randomized clinical trial. Secondary
      objective is the evaluation of pharmacogenetic factors contributing to drug efficacy in
      treatment resistant depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>after monotherapy and after augmentation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self reported psychopathology (Beck Depression Inventory [BDI], State-Trait Anxiety Inventory [STAI])</measure>
    <time_frame>after monotherapy and after augmentation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>after monotherapy and after augmentation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine augmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>&quot;Placebo&quot; augmentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)</description>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Trevilor retard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine up to 200 mg/d for four weeks</description>
    <arm_group_label>Verum</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male inpatients with a major depressive disorder without psychotic features
             or with a depressive episode within a bipolar I or II disorder without psychotic
             features

          -  Ages between 20 and 70 years

          -  Total score greater than 18 on the Hamilton Depression Rating Scale

          -  Documentation of at least one ineffective antidepressant drug trial under adequate
             dosage for at least 6 weeks in the current episode

        Exclusion Criteria:

          -  Other psychiatric axis I disorders than those mentioned as Inclusion criteria

          -  Acute suicidality (Item 3 of the Hamilton Depression Rating Scale greater than 2)

          -  Drug or alcohol addiction

          -  Patients with severe hepatic, cardiovascular, neurologic, metabolic or malignant
             disorders

          -  Documentation or report of a previous ineffective treatment trial with venlafaxine,
             lamotrigine or quetiapine

          -  Functional kidney disorders

          -  Untreated hypertension

          -  Acute treatment with thyroid hormone (less than 3 months)

          -  Pregnant or nursing patients

          -  Women of childbearing age without effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Holsboer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Max-Planck-Institute of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Max Planck Institute of Psychiatry</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment resistant depression</keyword>
  <keyword>Augmentation</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

